Physician profile
Michael S Gainey
NPI 1194796169
$2,296.72
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55.31 · 2020: $215 · 2021: $629 · 2022: $738 · 2023: $659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $659.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $659.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $386.74 | 2020-2023 | Austedo Xr, Austedo, Uzedy |
| Abbvie INC. | $241.63 | 2021-2023 | |
| Glaxosmithkline, LLC. | $182.15 | 2019-2022 | |
| Pfizer INC. | $125.56 | 2019-2021 | |
| Dexcom, INC. | $116.23 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $102.07 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $89.08 | 2023 | |
| Neurocrine Biosciences, INC. | $87.93 | 2022-2023 | Ingrezza |
| Astellas Pharma US INC | $75.16 | 2020-2023 | Myrbetriq |
| Novo Nordisk INC | $74.11 | 2020-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $73.71 | 2021-2022 | |
| Lilly USA, LLC | $64.93 | 2021-2023 | Mounjaro |
| Gilead Sciences, INC. | $62.69 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $52.17 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $48.73 | 2022-2023 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gainey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.